Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-20
2009-06-16
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S173100, C435S326000, C435S328000, C435S332000, C435S334000, C435S343000, C435S343100, C435S346000, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700
Reexamination Certificate
active
07547438
ABSTRACT:
Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5463564 (1995-10-01), Agrafiotis et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5723322 (1998-03-01), Guettler et al.
patent: 5801227 (1998-09-01), Fanslow, III et al.
patent: 5901069 (1999-05-01), Agrafiotis et al.
patent: 6106835 (2000-08-01), Chang et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6497876 (2002-12-01), Maraskovsky et al.
patent: 7172759 (2007-02-01), Thomas et al.
patent: 2003/0022860 (2003-01-01), Melief et al.
patent: 98/01873 (1998-11-01), None
patent: WO 99/61057 (1999-12-01), None
patent: WO 99/61065 (1999-12-01), None
patent: WO 02/11763 (2002-02-01), None
Jeffrey A. Ledbetter, et al.; “Agonistic Activity Of A CD40-Specific Single-Chain Fv Constructed From The Variable Regions Of mAb G28-5”;Critical Reviews In Immunology, vol. 17, Issue 1, pp. 427-435; 1997.
Zhao-hua Zhou et al.; “An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation And Maturation And Inhibits Proliferation Of A Myeloma Cell Line”;Hybridoma, vol. 18, No. 6, pp. 471-478; 1999.
Bjorck, P. et al.; “CD40 Antibodies Defining Distinct Epitopes Display Qualitative Differences In Their Induction Of B-Cell Differentiation”;Immunology, Blackwell Scientific Publications, GB, vol. 87, pp. 291-295; 1996, XP002930984 ISSN: 0019-2805.
Challa, A. et al., “Epitope-dependent Synergism And Antagonism Between CD40 Antibodies And Soluble CD40 Ligand For The Regulation Of CD23 Expression And IgE Synthesis In Human B Cells”;Allergy(Copenhagen), vol. 54, No. 6, pp. 576-583; Jun. 1999. XP002276806 ISSN: 0105-4538.
Dullforce, P. et al., “Enhancement Of T Cell-Independent Immune Responses In Vivo By CD40 Antibodies”;Nature Medicine Nature Publishing Co., US, vol. 4, No. 1, pp. 88-91; Jan. 1998. XP009026323 ISSN: 1078-8956.
French, R. et al., “CD40 Antibody Evokes A Cytotoxic T-cell Response That Eradicates Lymphoma And Bypasses T-cell Help”;Nature Medicine, Nature Publishing, CO, US, vol. 5, No. 5, pp. 548-553; May 1999. XP002159390 ISSN: 1078-8956.
Bjorck et al. “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40.”Immunology. Nov. 1994;83(3):430-7.
Heath et al. “Monoclonal antibodies to murine CD40 define two distinct functional epitopes.”Eur. J. Immunol.Aug. 1994;24(8):1828-34.
Holder et al. “Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction.”Eur. J. Immunol.Sep. 1993;23(9):2368-71.
Pellat-Deceunynck et al. “CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation.”Cancer Res.Apr. 15, 1996;56(8):1909-16.
Schwabe et al. “Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies.”Hybridoma.Jun. 1997;16(3):217-26.
Valle et al. “Activation of human B lymphocytes through CD40 and interleukin 4.”Eur. J. Immunol.Aug. 1998;19(8):1463-7.
Ngo et al. In the Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (Ed.) Birkhauser Boston, MA pp. 433, 492-495.
Skolnick et al. Trends in Biotech. 18: 34-39(2000).
Kuntz Science 257: 1078-1082 1992.
Coux et al. Research in Immunology 145: 235-239 (1994).
Zhou et al. Hybridoma 18: 471-478 (1999).
Katira et al. In Leukocyte Typing V, Schlossman(Ed) Oxford University Press Oxford 1995, p. 554.
Heath et al. Eur. J. Immunol. 24: 1818-1834(1994).
Guerder et al., “A fail-safe mechanism for maintaining self-tolerance”,J. Exp. Med.176(2):553-564 (1992).
Bennett, S.R.M., et al., “Help for Cytotoxic T-Cell Responses is Mediated By CD40 Signaling”,Nature393:478-480 (1998).
Schoenberger, S.P. et al., “T-Cell Help for Cytotoxic T-Lymphocytes is Mediated by CD40-CD40L Interactions”,Nature393:480-483 (1998).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands”,Curr. Opin. Immunol.6(3):407-13 (1994).
Alderson, et al., “CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40”,.J. Exp. Med.178(2):669-674 (1993).
Caux, et al., “B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells”,J Exp Med.180(5):1841-1847 (1994).
Riechmann, L., et al., “Reshaping Human Antibodies for Therapy”,Nature332: 323-327(1988).
Evans, M. J., et al., “Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector That Replicates in COS and 293 Cells”,J. Immunol. Meth.184: 123-138 (1995).
Tang, A. et al., “Suppression of Murine Allergic Contact Dermatitis by CTLA41g: Tolerance Induction of Th2 Responses Requires Additional Blockade of CD-40 Ligand”,J. Immunol.157:117-125 (1996).
Ridge, J. P. et al., “A Conditioned Dendritic Cell Can Be a Temporal Bridge Between a CD4+ T-Helper and a T-Killer Cell”,Nature393:474-477 (1998).
Caux, C. et al., “Activation of human dendritic cells through CD40 cross-linking” J Exp Med. 180(4):1263-1272 (1994).
Zhao-hua Zhou et al.; “The obtaining of an anti-human CD40 mono-clonal antibody with special functions and the analysis of its biological effects”; Chinese Journal of Immunology, vol. 15, No. 12, pp. 529-533; 1999.
Hilkens, C. M. U. et al.: “Human Dendritic Cells Require Exogenous Interleukin-12-Inducing Factors to Direct the Development of Naive T-Helper Cells Toward the TH1 Phenotype”;Blood, vol. 90, No. 5 (Sep. 1), 1997: pp. 1920-1926.
Pound, J.D. et al.; “Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells;”International Immunology, vol. 11, No. 1, pp. 11-20. (1999).
De Boer Mark
Res Pieter C. J. M.
Simone Peter J.
Thomas David
Darby & Darby P.C.
Gambel Phillip
Pangenetics BV
LandOfFree
CD40-binding activating antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD40-binding activating antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD40-binding activating antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081075